Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Ketamine hydrochloride
Drug ID BADD_D01229
Description Ketamine is an NMDA receptor antagonist with a potent anesthetic effect.[A31869] It was developed in 1963 as a replacement for phencyclidine (PCP) by Calvin Stevens at Parke Davis Laboratories. It started being used for veterinary purposes in Belgium and in 1964 was proven that compared to PCP, it produced minor hallucinogenic effects and shorter psychotomimetic effects. It was FDA approved in 1970, and from there, it has been used as an anesthetic for children or patients undergoing minor surgeries but mainly for veterinary purposes.[L1332]
Indications and Usage Reports have indicated a potential use of ketamine as a therapeutic tool for the management of depression when administered in lower doses.[A31873] These reports have increased the interest for ketamine in this area and several clinical trials are launched for this indication.[L1337, A31874]
Marketing Status Prescription; Discontinued
ATC Code N01AX03
DrugBank ID DB01221
KEGG ID D00711
MeSH ID D007649
PubChem ID 15851
TTD Drug ID D0UM7O
NDC Product Code 67457-108; 42023-115; 71872-7258; 52584-038; 0143-9509; 51927-2790; 70518-2787; 72572-320; 72572-321; 55150-438; 0404-9882; 0143-9508; 0409-2051; 52584-040; 10920-597; 38779-2880; 62991-1087; 55150-440; 42023-114; 56087-5442; 0404-9880; 0404-9881; 54382-114; 51552-0697; 67457-001; 60592-401; 67457-181; 63275-9980; 52584-037; 0409-2053; 42023-113; 49452-3912; 55150-439; 61281-8000; 51927-0120; 38779-1754
Synonyms Ketamine | 2-(2-Chlorophenyl)-2-(methylamino)cyclohexanone | CI-581 | CI 581 | CI581 | Ketalar | Ketaset | Ketanest | Calipsol | Kalipsol | Calypsol | Ketamine Hydrochloride
Chemical Information
Molecular Formula C13H17Cl2NO
CAS Registry Number 1867-66-9
SMILES CNC1(CCCCC1=O)C2=CC=CC=C2Cl.Cl
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
HyperglycaemiaCorticoliberinP01143Not AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Anaphylactic reaction24.06.03.006; 10.01.07.001--
Arrhythmia02.03.02.001--Not Available
Blood pressure increased13.14.03.005--Not Available
Bradycardia02.03.02.002--Not Available
Diplopia17.17.01.005; 06.02.06.002--Not Available
Erythema23.03.06.001--Not Available
Heart rate increased13.14.04.002--Not Available
Hypotension24.06.03.002--
Laryngospasm22.04.02.002--
Nausea07.01.07.001--
Nystagmus17.02.02.006; 06.05.02.006--
Pain08.01.08.004--
Rash23.03.13.001--Not Available
Respiratory depression22.02.01.010; 17.02.05.047--Not Available
Seizure17.12.03.001--
Vomiting07.01.07.003--
Decreased appetite14.03.01.005; 08.01.09.028--
The 1th Page    1    Total 1 Pages